- Home
- / DalCor Pharmaceuticals
DalCor Pharmaceuticals
Total Funding
$150 M
DalCor Pharmaceuticals Summary
Company Summary
- Overview
- DalCor Pharmaceuticals is company developing precision treatments for cardiovascular disease. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, a treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile.
- Type
- Private
- Status
- Active
- Founded
- 2015
- HQ
- Montréal, CA | view all locations
- Cybersecurity rating
Table of Contents
Key People
Fouzia Laghrissi-Thode, Chief Executive Officer, Director
Michael Dixon, Chief Financial Officer
A. Rachel Leheny, Director
LocationsView all
4 locations detected
Montréal, QC HQ
Canada
1010 Rue Sherbrooke Ouest #408
Sarasota, FL
United States
677 N Washington Blvd #32
Zug, ZG
Switzerland
Baarerstrasse 2
London, England
United Kingdom
Q3 The, Randalls Way, Holborn